Side effects of immunomodulatory drugs in the treatment of Multiple Sclerosis
experience in 118 cases
DOI:
https://doi.org/10.34024/rnc.2009.v17.8545Keywords:
Multiple Sclerosis, Immunologic Factors, Side Effects, HandlingAbstract
Immunomodulatory drugs are the most widely prescribed for patients with multiple sclerosis, with reduction of the relapse rate and disease activity, although the occurrence of adverse effects affects strongly on treatment adherence. Objective: To relate the adverse effects profile in MS patients treated with immunomodulatory drugs during five years period, and their management that might improve adherence. Method: We analyzed retrospectively 276 patients charts registered at CATEM, considering the use of one immunomodulatory drug and the migration between two or three drugs, at least for 5 years, and the adverse effects were classified in mild, moderate and severe. Results: We related the occurrence of adverse effects in 118 (42.7%) patients, 50 (42.3%) with mild effects, 45 (38.1%) moderate and 23 (19.4%) severe. The most common adverse effects were site injections reactions in 31 (26.2%), and moderate in 17 (14.4%). There were adverse effects in 42 (47.7%) of 88 INFβ-1b SC patients, in 41 (54.6%) of 75 INFβ1a SC patients, in 16 (25.8%) of 62 INFβ-1a IM patients, and in 19 (37.2%) of 51 Glatiramer Acetate patients. Conclusions: The adverse effects during immunomodulatory treatment are common and their correct management impacts strongly in patient’s adherence.
Metrics
References
Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler 2007;13:1146-52.
Frohman EM, Brannon K, Alexander S, Sims D, Phillips JT, O’Leary S, et al. Disease modifying agents related skin reactions in multiple sclerosis: prevention, assessment and management. Mult Scler 2004;10:302-7.
The IFN beta Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing-remitting muyltiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.
Jacobs LD, Cookfair DL, Rudick, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, Eckhardt J, et al. Treatment adherence and patient retention in the first year of a phase III clinical trial for the treatment of multiple sclerosis. Mult Scler 1999;53:192-7.
Hadjimichael O, Volmer TL. Adherence to injection therapy in multiple sclerosis: patient survey. Neurology 1999;53:1190-7.
Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61:551-4.
Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002;58:169-78.
Rio J, Porcel J, Téllez N. Factors related with adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult Scle 2005;11:306-9.
O΄Rourke K, Hutchinson M. Analysis of stopping patterns in INFB therapay. Mul Scler 2005;11:46-50.
Jordy SS, Tilbery CP, Fazzito MM. Immunomodulatot therapy migration in relapsing remitting multiple sclerosis. A study of 152 cases. Arq Neuropsiquiatr 2008;66:11-4.
Mohr DC, Goodking DE, Likosky W, Dwyer P. Therapeutic expectations of patients with multipla sclerosis upon iniating interferon beta -1b: relationship to adherence to treatment. Mult Scler 1996;2:222-6.
Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, et al. Interferon beta in multiple sclerosis: .experience in a British specialist multiple sclerosis centre J Neurol Neurosurg Psychiatr 2003;74:946-9.
Baum K, Leary CO, Ferrer FC, Klímová E, Procházková L, Bugge J, et al. Comparison of injection site pain and injection site reactions in relapsing-remiting multiple sclerosis patients treated with interferon beta-1a or 1b. Mult Scler 2007;13:1153-60.
Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta 1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-8.
Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferongamma-secreting cells in multiple sclerosis treated with interferon beta 1-b. Neurology 1995;45:2173-7.
Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol 1994;17:495-547.
Walter EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7.
Munschauer FE, Kinkel RP. Managing side effects of interferon beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-93.
Rio J, Nos C, Marzo ME, Tintoré M, Montalban X. Low-dose steroids reduce flu-like symptoms at the initistion of INF beta 1b in relapsing-remitting MS. Neurology 1998;50:1910-2.
Agras S, Sylvester D, Oliveau D. The epidemiology of bloodinjection-injury phobia. Psychol Med 1998;28:1129-36.
Costello CG. Fears and phobias in women: a community study. J Abnorm Psychol 1982;4:280-6.
Cox D, Mohr DC. Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety. Am J Drug Deliv 2003;1:215-21.
Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10:115-50.
European Study Group on Interferon beta 1b in secondary progressive MS. Placebo-controlled multicentre randomized trial of interferon beta 1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352: 1491-7.
PRISMS (Prevention of relapses, disability by interferon beta 1a subcutaneously in multiple sclerosis). Study Group. Randomized double-blind placebo-controlled study of interferon beta 1 a in relapsing/remitting multipla sclerosis. Lancet 1998;352:1498-504.
Fukunishi K, Tanaka H, Marruyama J, Takahashi M, Ueshima K, Sakata I, et al. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998;24:581-3.
Borras C, Rio J, Porcel J, Barrios M, Tintore M, Montalben X. Emotional state of patients with relapsing-remitting MS treated with interferon beta 1b. Neurology 1999;52:1636-9.
Tremlett HL, Oger J. Ten years of adverse drug reactions reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler 2008;14:94-105.
Gaines AR, Varricchio F. Interferon beta 1b injection site reactions and necroses. Mult Scler 1998;4:70-3.
